HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis.

Abstract
Data regarding the role of inhaled colistin in critically ill pediatric patients without cystic fibrosis are scarce. Three children (one female), admitted to the intensive care unit (ICU) of a tertiary-care pediatric hospital in Athens, Greece, during 2004-2009 received inhaled colistin as monotherapy for tracheobronchitis (two children), and as adjunctive therapy for necrotizing pneumonia (one child). Colistin susceptible Acinetobacter baumannii and Pseudomonas aeruginosa were isolated from the cases' bronchial secretions specimens. All three children received inhaled colistin at a dosage of 75 mg diluted in 3 ml of normal saline twice daily (1,875,000 IU of colistin daily), for a duration of 25, 32, and 15 days, respectively. All three children recovered from the infections. Also, a gradual reduction, and finally total elimination of the microbial load in bronchial secretions was observed during inhaled colistin treatment in the reported cases. All three cases were discharged from the ICU. No bronchoconstriction or any other type of toxicity of colistin was observed. In conclusion, inhaled colistin was effective and safe for the treatment of two children with tracheobronchitis, and one child with necrotizing pneumonia. Further studies are needed to clarify further the role of inhaled colistin in pediatric critically ill patients without cystic fibrosis.
AuthorsMatthew E Falagas, Georgia Sideri, Ioanna P Korbila, Evridiki K Vouloumanou, John H Papadatos, Dimitris A Kafetzis
JournalPediatric pulmonology (Pediatr Pulmonol) Vol. 45 Issue 11 Pg. 1135-40 (Nov 2010) ISSN: 1099-0496 [Electronic] United States
PMID20658485 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Bronchodilator Agents
  • Ipratropium
  • Albuterol
  • Colistin
Topics
  • Acinetobacter Infections (drug therapy)
  • Acinetobacter baumannii (drug effects, isolation & purification)
  • Administration, Inhalation
  • Albuterol (therapeutic use)
  • Anti-Bacterial Agents (administration & dosage, adverse effects, therapeutic use)
  • Bronchitis (complications, drug therapy)
  • Bronchodilator Agents (therapeutic use)
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Colistin (administration & dosage, adverse effects, therapeutic use)
  • Critical Care
  • Critical Illness
  • Cystic Fibrosis (complications)
  • Female
  • Hospitals, Pediatric
  • Humans
  • Infant
  • Ipratropium (therapeutic use)
  • Male
  • Pneumonia, Bacterial (complications, drug therapy)
  • Pseudomonas Infections (drug therapy)
  • Pseudomonas aeruginosa (drug effects, isolation & purification)
  • Tracheitis (complications, drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: